FDA clears wearable Sarclisa as HHS advances antidepressant deprescribing

The U.S. drug regulation and health policy environment produced two distinct signals for the pharmaceutical sector in close succession. The Food and Drug Administration approved a wearable formulation of Sanofi's multiple myeloma drug Sarclisa, making it the first cancer treatment cleared for delivery through an on-body injector attached to the skin. On the policy side, Health and Human Services Secretary Robert F. Kennedy Jr. is moving forward with a structured effort to develop clinical guidance that would help providers instruct patients on tapering off antidepressants.

Sarclisa: what the wearable approval changes

The approved device cuts median administration time for Sarclisa from up to three hours via intravenous infusion to 13 minutes. That number matters for oncology clinics running multiple treatment courses daily. Capacity pressure in infusion centers has been sector-wide, and a format that keeps patients out of the infusion chair for most of their visits carries direct implications for clinic staffing and scheduling.

Multiple myeloma requires sustained, repeated treatment. A patient cycling through multiple courses of Sarclisa accumulates a significant infusion burden under the IV format across a full treatment arc. How broadly uptake spreads in clinical practice will depend on reimbursement alignment and provider adoption, but the baseline efficiency case is straightforward: 13 minutes against three hours.

The deprescribing initiative and what remains unresolved

The HHS effort is in its early stages. Earlier this month, dozens of mental health professionals met with federal health officials to identify research gaps around deprescribing SSRIs, including how side effects vary by drug and by how long the patient was taking it. A senior HHS official confirmed the discussion and described the work as mapping out forthcoming clinical guidance.

That framing matters. The meeting produced no finalized protocol. The side-effect variability the HHS official acknowledged signals that any guidance will need to account for individual patient circumstances. Deprescribing psychiatric medications carries more clinical complexity than comparable efforts in other therapeutic areas because withdrawal profiles differ across the SSRI class, and the evidence base around best practices remains incomplete by the agency's own account.

The read-through for the broader cycle

The two developments pull in different directions for demand. The Sarclisa wearable approval removes an access friction for an existing drug, a development that could expand the treated population by making repeat dosing less burdensome for patients and the clinics serving them. The HHS antidepressant effort, if it produces widely adopted guidance, applies pressure to SSRI prescription volumes, a market with cross-border relevance given the influence U.S. clinical standards carry internationally.

The macro caveat is implementation lag. Clinical guidance requires provider adoption to affect actual prescription behavior, and adoption timelines across health systems are typically measured in years. The Sarclisa data point is more immediate: a clinic administrator comparing 13 minutes against three hours does not need a guideline to understand the arithmetic.